Cytotoxicity assessment of heparin nanoparticles in NR8383 macrophages

Abstract : The bioavailability of low molecular weight heparin (LMWH) has been increased by encapsulation in nanoparticles. As a complement to these results, the cytotoxicity and apoptosis induced by LMWH nanoparticles prepared by two methods [nanoprecipitation (NP) and double emulsion (DE)] using Eudragit® RS (RS) and poly-ɛ-caprolactone (PCL) have been analysed. Particle sizes varied from 54 to 400 nm with zeta potential values between −65 and +63 mV. Our results showed that the method of nanoparticle preparation affects their properties, especially in terms of drug incorporation and cell tolerance. Cell viability ranged from 6% to 100% depending on the preparation method and physicochemical properties of the particles and the type of toxicity assay. Particle diameter and zeta potential seemed to be the most valuable cytotoxicity markers when cell viability was measured by Trypan blue exclusion and MTT respectively. Nanoparticles prepared by DE were better tolerated than those of NP. LMWH encapsulation into the cationic nanoparticles reduces remarkably their toxicity. Apoptosis evaluation showed activated caspases in exposed cells. However, no nuclear fragmentation was detected in NR8383 cells whatever the tested nanoparticles. DE nanoparticles of RS and PCL can be proposed as a good LMWH delivery system due to their low toxicity (IC50 ∼ 2.33 and 0.96 mg/mL, respectively).
Type de document :
Article dans une revue
International Journal of Pharmaceutics, Elsevier, 2010, 396 (1-2), pp.156 - 165. 〈10.1016/j.ijpharm.2010.06.006〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01650309
Contributeur : Raphaël Duval <>
Soumis le : mardi 28 novembre 2017 - 13:29:28
Dernière modification le : dimanche 7 octobre 2018 - 16:52:01

Identifiants

Citation

H. Eidi, O. Joubert, G. Attik, Raphaël E. Duval, M.C. Bottin, et al.. Cytotoxicity assessment of heparin nanoparticles in NR8383 macrophages. International Journal of Pharmaceutics, Elsevier, 2010, 396 (1-2), pp.156 - 165. 〈10.1016/j.ijpharm.2010.06.006〉. 〈hal-01650309〉

Partager

Métriques

Consultations de la notice

58